Share Price and Basic Stock Data
Last Updated: October 18, 2025, 6:36 pm
| PEG Ratio | 5.30 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Shilpa Medicare Ltd operates in the pharmaceuticals sector, with a market capitalization of ₹7,150 Cr and a current share price of ₹365. The company reported sales of ₹1,046 Cr for the fiscal year ending March 2023, which increased marginally to ₹1,146 Cr in March 2024, reflecting a growth trajectory. For the trailing twelve months (TTM), sales stood at ₹1,315 Cr, indicating a robust upward movement. Quarterly sales figures also show a positive trend, with ₹313 Cr in September 2023 and further rising to ₹344 Cr by September 2024. The company’s operating profit margin (OPM) improved significantly from 9% in March 2023 to 25% in March 2025, illustrating enhanced operational efficiency. However, the increase in sales has not always translated into net profit, as evident from the ₹78 Cr net profit reported for March 2025, following a loss of ₹31 Cr in March 2023. This fluctuation in profitability signals the potential volatility that Shilpa Medicare may experience as it navigates the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Shilpa Medicare’s profitability metrics have shown variability over recent quarters. The net profit for March 2025 was ₹78 Cr, recovering from a loss of ₹31 Cr the previous year. The earnings per share (EPS) improved to ₹8.01 for March 2025, up from negative ₹3.74 in March 2023. The operating profit margin (OPM) has progressively increased, reaching 25% in March 2025 compared to just 9% in March 2023, indicating improved cost management and operational efficiency. Furthermore, the interest coverage ratio (ICR) stood at 4.50x, suggesting that the company generates sufficient earnings to cover its interest expenses comfortably. However, the company’s return on equity (ROE) remains modest at 4.21%, which may not appeal to all investors. The cash conversion cycle, although lengthening to 350 days, highlights potential inefficiencies in inventory or receivables management, which could be a concern moving forward.
Balance Sheet Strength and Financial Ratios
Shilpa Medicare’s balance sheet reflects a mixed picture of financial health. The company has total borrowings of ₹588 Cr against reserves of ₹2,362 Cr, highlighting a favorable reserves-to-debt ratio and indicating that it is not overly reliant on leverage. The debt-to-equity ratio stands at 0.24, which is relatively low, suggesting that the company maintains a conservative approach to debt management. The current ratio is reported at 1.46, indicating that it has more than enough current assets to cover its current liabilities, which bodes well for liquidity. However, the quick ratio of 0.94 suggests that without inventory, the company may face challenges in meeting short-term obligations. Additionally, the price-to-book value ratio at 2.73x may indicate that the stock is trading at a premium compared to its book value, which could warrant caution for potential investors looking for value.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Shilpa Medicare reveals a diverse mix of ownership, with promoters holding 44.23% as of March 2025, down from 50.01% in September 2022. This decline may indicate a shift in investor sentiment or dilution of promoter holdings. Foreign institutional investors (FIIs) have increased their stake to 11.19%, suggesting growing confidence from international investors. Domestic institutional investors (DIIs) hold 7.46%, while the public owns 37.10% of the company. The total number of shareholders has seen fluctuations, with 48,636 reported as of March 2025, reflecting a slight decline from the peak of 50,434 in June 2023. This mixed ownership structure could lead to varied influences on corporate governance and strategic direction, impacting overall investor confidence.
Outlook, Risks, and Final Insight
If margins sustain their upward trajectory and operational efficiencies are improved further, Shilpa Medicare could enhance its profitability significantly. However, the increasing cash conversion cycle and modest ROE present risks that may hinder growth. Furthermore, external factors such as regulatory changes in the pharmaceutical sector could impact operational performance. The company’s ability to manage its inventory and receivables efficiently will be crucial in maintaining liquidity. Should Shilpa Medicare successfully navigate these challenges and capitalize on its strengths, including a strong balance sheet and improving sales, it could position itself favorably within the competitive landscape of the Indian pharmaceutical industry, potentially leading to enhanced shareholder value over time.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Shilpa Medicare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 117 | 247/84.3 | 33.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,702 Cr. | 432 | 440/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.94 Cr | 1,185.68 | 50.47 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 261 | 263 | 262 | 264 | 260 | 313 | 287 | 292 | 293 | 344 | 319 | 331 | 321 |
| Expenses | 241 | 253 | 231 | 227 | 214 | 255 | 222 | 222 | 222 | 258 | 239 | 254 | 231 |
| Operating Profit | 20 | 10 | 31 | 37 | 46 | 58 | 65 | 70 | 70 | 86 | 81 | 77 | 91 |
| OPM % | 8% | 4% | 12% | 14% | 18% | 19% | 23% | 24% | 24% | 25% | 25% | 23% | 28% |
| Other Income | 8 | 4 | 3 | 2 | 2 | 2 | 2 | 9 | 10 | 5 | 1 | -18 | 6 |
| Interest | 10 | 13 | 18 | 18 | 18 | 23 | 26 | 24 | 24 | 26 | 12 | 14 | 19 |
| Depreciation | 22 | 23 | 24 | 26 | 27 | 28 | 27 | 27 | 27 | 28 | 29 | 29 | 29 |
| Profit before tax | -4 | -22 | -8 | -4 | 3 | 9 | 14 | 28 | 29 | 37 | 42 | 15 | 50 |
| Tax % | -158% | -17% | -13% | 90% | 64% | 83% | 67% | 12% | 51% | 51% | 24% | 5% | 5% |
| Net Profit | 2 | -19 | -7 | -8 | 1 | 2 | 5 | 24 | 14 | 18 | 32 | 15 | 47 |
| EPS in Rs | 0.10 | -2.15 | -0.76 | -0.93 | 0.14 | 0.19 | 0.53 | 2.82 | 1.44 | 1.83 | 3.25 | 1.48 | 4.79 |
Last Updated: August 20, 2025, 3:50 am
Below is a detailed analysis of the quarterly data for Shilpa Medicare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 321.00 Cr.. The value appears to be declining and may need further review. It has decreased from 331.00 Cr. (Mar 2025) to 321.00 Cr., marking a decrease of 10.00 Cr..
- For Expenses, as of Jun 2025, the value is 231.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 254.00 Cr. (Mar 2025) to 231.00 Cr., marking a decrease of 23.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 91.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Mar 2025) to 91.00 Cr., marking an increase of 14.00 Cr..
- For OPM %, as of Jun 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Mar 2025) to 28.00%, marking an increase of 5.00%.
- For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from -18.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 24.00 Cr..
- For Interest, as of Jun 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 5.00 Cr..
- For Depreciation, as of Jun 2025, the value is 29.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 29.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 35.00 Cr..
- For Tax %, as of Jun 2025, the value is 5.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00%.
- For Net Profit, as of Jun 2025, the value is 47.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Mar 2025) to 47.00 Cr., marking an increase of 32.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.79. The value appears strong and on an upward trend. It has increased from 1.48 (Mar 2025) to 4.79, marking an increase of 3.31.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:28 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 571 | 614 | 719 | 779 | 789 | 733 | 908 | 899 | 1,141 | 1,046 | 1,146 | 1,281 | 1,315 |
| Expenses | 455 | 485 | 566 | 614 | 634 | 585 | 688 | 718 | 940 | 947 | 907 | 965 | 981 |
| Operating Profit | 116 | 129 | 153 | 165 | 155 | 148 | 219 | 181 | 202 | 99 | 239 | 316 | 334 |
| OPM % | 20% | 21% | 21% | 21% | 20% | 20% | 24% | 20% | 18% | 9% | 21% | 25% | 25% |
| Other Income | 6 | 5 | 5 | 15 | 22 | 33 | 17 | 90 | 21 | 17 | 15 | -5 | -5 |
| Interest | 4 | 4 | 7 | 3 | 3 | 4 | 5 | 22 | 41 | 59 | 92 | 76 | 71 |
| Depreciation | 23 | 21 | 29 | 31 | 37 | 42 | 44 | 54 | 80 | 96 | 108 | 113 | 115 |
| Profit before tax | 95 | 108 | 122 | 146 | 137 | 136 | 188 | 195 | 102 | -38 | 54 | 122 | 143 |
| Tax % | 21% | 33% | 19% | 29% | 25% | 19% | 18% | 25% | 41% | -19% | 41% | 36% | |
| Net Profit | 75 | 73 | 99 | 104 | 103 | 110 | 155 | 146 | 61 | -31 | 32 | 78 | 111 |
| EPS in Rs | 5.14 | 4.78 | 6.73 | 6.71 | 6.45 | 6.88 | 9.57 | 9.06 | 3.49 | -1.87 | 1.84 | 4.00 | 5.68 |
| Dividend Payout % | 5% | 6% | 4% | 4% | 5% | 7% | 6% | 6% | 16% | -0% | -0% | 12% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2.67% | 35.62% | 5.05% | -0.96% | 6.80% | 40.91% | -5.81% | -58.22% | -150.82% | 203.23% | 143.75% |
| Change in YoY Net Profit Growth (%) | 0.00% | 38.28% | -30.57% | -6.01% | 7.76% | 34.11% | -46.72% | -52.41% | -92.60% | 354.05% | -59.48% |
Shilpa Medicare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 7% |
| 3 Years: | 4% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -11% |
| 3 Years: | 16% |
| TTM: | 213% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 11% |
| 3 Years: | 29% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 1:26 pm
Balance Sheet
Last Updated: September 10, 2025, 2:28 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 |
| Reserves | 389 | 539 | 639 | 979 | 1,077 | 1,189 | 1,321 | 1,471 | 1,814 | 1,775 | 1,800 | 2,362 |
| Borrowings | 118 | 189 | 221 | 241 | 191 | 194 | 390 | 846 | 683 | 798 | 937 | 588 |
| Other Liabilities | 163 | 169 | 194 | 244 | 223 | 218 | 270 | 308 | 370 | 323 | 347 | 351 |
| Total Liabilities | 678 | 905 | 1,062 | 1,472 | 1,499 | 1,610 | 1,989 | 2,632 | 2,876 | 2,904 | 3,093 | 3,311 |
| Fixed Assets | 294 | 316 | 580 | 492 | 534 | 558 | 650 | 1,111 | 1,342 | 1,368 | 1,385 | 1,418 |
| CWIP | 111 | 222 | 95 | 141 | 210 | 429 | 666 | 541 | 506 | 655 | 719 | 822 |
| Investments | 10 | 66 | 53 | 253 | 140 | 2 | 10 | 21 | 34 | 43 | 40 | 35 |
| Other Assets | 262 | 301 | 334 | 587 | 615 | 621 | 662 | 959 | 993 | 838 | 950 | 1,037 |
| Total Assets | 678 | 905 | 1,062 | 1,472 | 1,499 | 1,610 | 1,989 | 2,632 | 2,876 | 2,904 | 3,093 | 3,311 |
Below is a detailed analysis of the balance sheet data for Shilpa Medicare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2024) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Mar 2025, the value is 2,362.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,800.00 Cr. (Mar 2024) to 2,362.00 Cr., marking an increase of 562.00 Cr..
- For Borrowings, as of Mar 2025, the value is 588.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 937.00 Cr. (Mar 2024) to 588.00 Cr., marking a decrease of 349.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 351.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 347.00 Cr. (Mar 2024) to 351.00 Cr., marking an increase of 4.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 3,311.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,093.00 Cr. (Mar 2024) to 3,311.00 Cr., marking an increase of 218.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,418.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,385.00 Cr. (Mar 2024) to 1,418.00 Cr., marking an increase of 33.00 Cr..
- For CWIP, as of Mar 2025, the value is 822.00 Cr.. The value appears strong and on an upward trend. It has increased from 719.00 Cr. (Mar 2024) to 822.00 Cr., marking an increase of 103.00 Cr..
- For Investments, as of Mar 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2024) to 35.00 Cr., marking a decrease of 5.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,037.00 Cr.. The value appears strong and on an upward trend. It has increased from 950.00 Cr. (Mar 2024) to 1,037.00 Cr., marking an increase of 87.00 Cr..
- For Total Assets, as of Mar 2025, the value is 3,311.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,093.00 Cr. (Mar 2024) to 3,311.00 Cr., marking an increase of 218.00 Cr..
Notably, the Reserves (2,362.00 Cr.) exceed the Borrowings (588.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -60.00 | -68.00 | -76.00 | -36.00 | -46.00 | -171.00 | -665.00 | -481.00 | -699.00 | -698.00 | -272.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43 | 48 | 43 | 80 | 102 | 101 | 99 | 88 | 124 | 113 | 125 | 126 |
| Inventory Days | 143 | 147 | 161 | 187 | 194 | 266 | 298 | 427 | 338 | 280 | 309 | 309 |
| Days Payable | 108 | 85 | 101 | 110 | 106 | 115 | 122 | 91 | 139 | 125 | 156 | 85 |
| Cash Conversion Cycle | 79 | 111 | 104 | 157 | 189 | 253 | 275 | 425 | 323 | 268 | 278 | 350 |
| Working Capital Days | 30 | 33 | 27 | 79 | 98 | 98 | 68 | 72 | 77 | -13 | 48 | 81 |
| ROCE % | 20% | 18% | 16% | 14% | 10% | 9% | 12% | 8% | 6% | 1% | 5% | 8% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal Nifty Microcap 250 Index Fund | 48,903 | 0.26 | 1.62 | 48,903 | 2025-04-22 17:25:21 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 405 | 0.14 | 0.01 | 405 | 2025-04-22 17:25:21 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 8.04 | 3.67 | -3.74 | 7.26 | 18.13 |
| Diluted EPS (Rs.) | 8.04 | 3.67 | -3.74 | 7.26 | 18.13 |
| Cash EPS (Rs.) | 19.70 | 16.66 | 7.88 | 16.59 | 24.77 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 242.65 | 208.37 | 204.41 | 208.65 | 180.00 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 242.65 | 208.37 | 204.41 | 208.65 | 180.00 |
| Revenue From Operations / Share (Rs.) | 131.59 | 132.67 | 120.98 | 131.97 | 110.53 |
| PBDIT / Share (Rs.) | 34.80 | 29.11 | 13.79 | 25.13 | 25.98 |
| PBIT / Share (Rs.) | 23.24 | 16.68 | 2.79 | 15.93 | 19.36 |
| PBT / Share (Rs.) | 12.64 | 6.81 | -3.97 | 12.20 | 24.14 |
| Net Profit / Share (Rs.) | 8.14 | 4.23 | -3.12 | 7.40 | 18.15 |
| NP After MI And SOA / Share (Rs.) | 8.01 | 3.67 | -3.74 | 6.99 | 18.13 |
| PBDIT Margin (%) | 26.44 | 21.94 | 11.39 | 19.03 | 23.50 |
| PBIT Margin (%) | 17.66 | 12.57 | 2.30 | 12.07 | 17.51 |
| PBT Margin (%) | 9.60 | 5.13 | -3.28 | 9.24 | 21.83 |
| Net Profit Margin (%) | 6.18 | 3.18 | -2.58 | 5.60 | 16.41 |
| NP After MI And SOA Margin (%) | 6.08 | 2.76 | -3.09 | 5.29 | 16.39 |
| Return on Networth / Equity (%) | 3.30 | 1.76 | -1.82 | 3.32 | 9.99 |
| Return on Capital Employeed (%) | 8.61 | 6.03 | 1.14 | 6.10 | 7.75 |
| Return On Assets (%) | 2.36 | 1.03 | -1.11 | 2.10 | 5.60 |
| Long Term Debt / Equity (X) | 0.09 | 0.30 | 0.16 | 0.19 | 0.32 |
| Total Debt / Equity (X) | 0.24 | 0.51 | 0.44 | 0.37 | 0.48 |
| Asset Turnover Ratio (%) | 0.40 | 0.38 | 0.36 | 0.12 | 0.36 |
| Current Ratio (X) | 1.46 | 1.26 | 0.98 | 1.45 | 1.52 |
| Quick Ratio (X) | 0.94 | 0.76 | 0.57 | 0.86 | 0.99 |
| Inventory Turnover Ratio (X) | 1.01 | 1.28 | 1.10 | 0.35 | 1.16 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 14.78 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 6.38 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 85.22 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 93.62 | 0.00 |
| Interest Coverage Ratio (X) | 4.50 | 2.75 | 2.04 | 5.30 | 9.68 |
| Interest Coverage Ratio (Post Tax) (X) | 2.43 | 1.33 | 0.53 | 2.35 | 4.98 |
| Enterprise Value (Cr.) | 7030.92 | 4901.02 | 2756.04 | 4084.09 | 3310.97 |
| EV / Net Operating Revenue (X) | 5.47 | 4.26 | 2.62 | 3.57 | 3.67 |
| EV / EBITDA (X) | 20.67 | 19.40 | 23.03 | 18.73 | 15.63 |
| MarketCap / Net Operating Revenue (X) | 5.04 | 3.48 | 1.90 | 3.01 | 3.02 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 85.21 | 0.00 |
| Price / BV (X) | 2.73 | 2.21 | 1.12 | 1.89 | 1.84 |
| Price / Net Operating Revenue (X) | 5.04 | 3.48 | 1.90 | 3.01 | 3.02 |
| EarningsYield | 0.01 | 0.01 | -0.01 | 0.01 | 0.05 |
After reviewing the key financial ratios for Shilpa Medicare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.04. This value is within the healthy range. It has increased from 3.67 (Mar 24) to 8.04, marking an increase of 4.37.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.04. This value is within the healthy range. It has increased from 3.67 (Mar 24) to 8.04, marking an increase of 4.37.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.70. This value is within the healthy range. It has increased from 16.66 (Mar 24) to 19.70, marking an increase of 3.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 242.65. It has increased from 208.37 (Mar 24) to 242.65, marking an increase of 34.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 242.65. It has increased from 208.37 (Mar 24) to 242.65, marking an increase of 34.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 131.59. It has decreased from 132.67 (Mar 24) to 131.59, marking a decrease of 1.08.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 34.80. This value is within the healthy range. It has increased from 29.11 (Mar 24) to 34.80, marking an increase of 5.69.
- For PBIT / Share (Rs.), as of Mar 25, the value is 23.24. This value is within the healthy range. It has increased from 16.68 (Mar 24) to 23.24, marking an increase of 6.56.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.64. This value is within the healthy range. It has increased from 6.81 (Mar 24) to 12.64, marking an increase of 5.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.14. This value is within the healthy range. It has increased from 4.23 (Mar 24) to 8.14, marking an increase of 3.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.01. This value is within the healthy range. It has increased from 3.67 (Mar 24) to 8.01, marking an increase of 4.34.
- For PBDIT Margin (%), as of Mar 25, the value is 26.44. This value is within the healthy range. It has increased from 21.94 (Mar 24) to 26.44, marking an increase of 4.50.
- For PBIT Margin (%), as of Mar 25, the value is 17.66. This value is within the healthy range. It has increased from 12.57 (Mar 24) to 17.66, marking an increase of 5.09.
- For PBT Margin (%), as of Mar 25, the value is 9.60. This value is below the healthy minimum of 10. It has increased from 5.13 (Mar 24) to 9.60, marking an increase of 4.47.
- For Net Profit Margin (%), as of Mar 25, the value is 6.18. This value is within the healthy range. It has increased from 3.18 (Mar 24) to 6.18, marking an increase of 3.00.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.08. This value is below the healthy minimum of 8. It has increased from 2.76 (Mar 24) to 6.08, marking an increase of 3.32.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.30. This value is below the healthy minimum of 15. It has increased from 1.76 (Mar 24) to 3.30, marking an increase of 1.54.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.61. This value is below the healthy minimum of 10. It has increased from 6.03 (Mar 24) to 8.61, marking an increase of 2.58.
- For Return On Assets (%), as of Mar 25, the value is 2.36. This value is below the healthy minimum of 5. It has increased from 1.03 (Mar 24) to 2.36, marking an increase of 1.33.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. It has decreased from 0.30 (Mar 24) to 0.09, marking a decrease of 0.21.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.24, marking a decrease of 0.27.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.40. It has increased from 0.38 (Mar 24) to 0.40, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has increased from 1.26 (Mar 24) to 1.46, marking an increase of 0.20.
- For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.76 (Mar 24) to 0.94, marking an increase of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.01. This value is below the healthy minimum of 4. It has decreased from 1.28 (Mar 24) to 1.01, marking a decrease of 0.27.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.50. This value is within the healthy range. It has increased from 2.75 (Mar 24) to 4.50, marking an increase of 1.75.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 3. It has increased from 1.33 (Mar 24) to 2.43, marking an increase of 1.10.
- For Enterprise Value (Cr.), as of Mar 25, the value is 7,030.92. It has increased from 4,901.02 (Mar 24) to 7,030.92, marking an increase of 2,129.90.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.47. This value exceeds the healthy maximum of 3. It has increased from 4.26 (Mar 24) to 5.47, marking an increase of 1.21.
- For EV / EBITDA (X), as of Mar 25, the value is 20.67. This value exceeds the healthy maximum of 15. It has increased from 19.40 (Mar 24) to 20.67, marking an increase of 1.27.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.04. This value exceeds the healthy maximum of 3. It has increased from 3.48 (Mar 24) to 5.04, marking an increase of 1.56.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 2.73. This value is within the healthy range. It has increased from 2.21 (Mar 24) to 2.73, marking an increase of 0.52.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.04. This value exceeds the healthy maximum of 3. It has increased from 3.48 (Mar 24) to 5.04, marking an increase of 1.56.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Shilpa Medicare Ltd:
- Net Profit Margin: 6.18%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.61% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.3% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 54.2 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.18%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 12-6-214/A-1, Shilpa House, Raichur Karnataka 584135 | info@vbshilpa.com http://www.vbshilpa.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Omprakash Inani | Chairman |
| Mr. Vishnukant C Bhutada | Managing Director |
| Mr. Kalakota Sharath Reddy | Whole Time Director |
| Mr. Hetal Madhukant Gandhi | Independent Director |
| Mr. Arvind Vasudeva | Independent Director |
| Dr. Kamal K Sharma | Independent Director |
| Dr. Anita Bandyopadhyay | Independent Woman Director |
FAQ
What is the intrinsic value of Shilpa Medicare Ltd?
Shilpa Medicare Ltd's intrinsic value (as of 18 October 2025) is 221.19 which is 37.87% lower the current market price of 356.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 6,963 Cr. market cap, FY2025-2026 high/low of 502/265, reserves of ₹2,362 Cr, and liabilities of 3,311 Cr.
What is the Market Cap of Shilpa Medicare Ltd?
The Market Cap of Shilpa Medicare Ltd is 6,963 Cr..
What is the current Stock Price of Shilpa Medicare Ltd as on 18 October 2025?
The current stock price of Shilpa Medicare Ltd as on 18 October 2025 is 356.
What is the High / Low of Shilpa Medicare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Shilpa Medicare Ltd stocks is 502/265.
What is the Stock P/E of Shilpa Medicare Ltd?
The Stock P/E of Shilpa Medicare Ltd is 54.2.
What is the Book Value of Shilpa Medicare Ltd?
The Book Value of Shilpa Medicare Ltd is 121.
What is the Dividend Yield of Shilpa Medicare Ltd?
The Dividend Yield of Shilpa Medicare Ltd is 0.14 %.
What is the ROCE of Shilpa Medicare Ltd?
The ROCE of Shilpa Medicare Ltd is 7.82 %.
What is the ROE of Shilpa Medicare Ltd?
The ROE of Shilpa Medicare Ltd is 4.21 %.
What is the Face Value of Shilpa Medicare Ltd?
The Face Value of Shilpa Medicare Ltd is 1.00.